{"id":23398,"date":"2023-03-23T08:44:56","date_gmt":"2023-03-23T07:44:56","guid":{"rendered":"https:\/\/idibell.cat\/?p=23398"},"modified":"2024-11-21T15:18:28","modified_gmt":"2024-11-21T14:18:28","slug":"una-ajuda-de-la-fundacio-la-caixa-permet-a-albert-antolin-installar-la-seva-recerca-a-lidibell","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/03\/una-ajuda-de-la-fundacio-la-caixa-permet-a-albert-antolin-installar-la-seva-recerca-a-lidibell\/","title":{"rendered":"Una ajuda de la Fundaci\u00f3 \u201cla Caixa\u201d permet a Albert Antol\u00edn instal\u00b7lar la seva recerca a l\u2019IDIBELL"},"content":{"rendered":"<p>Les ajudes Junior Leader de La Fundaci\u00f3 &#8220;la Caixa&#8221; van destinades a investigadors excel\u00b7lents perqu\u00e8 duguin a terme els seus projectes en universitats i centres de recerca d&#8217;Espanya i Portugal. Aquest programa potencia la carrera cient\u00edfica independent com a opci\u00f3 de futur professional i fomenta la innovaci\u00f3 i el lideratge. D&#8217;entre les 557 sol\u00b7licituds rebudes, el Dr. Albert Antol\u00edn ha estat un dels 40 seleccionats, el que li ha perm\u00e8s establir-se a l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO) com investigador principal del <a href=\"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/cancer-de-mama\/\">grup de recerca en c\u00e0ncer de mama<\/a>.<\/p>\n<p>El programa de beques de la Fundaci\u00f3 &#8220;la Caixa&#8221; \u00e9s un dels m\u00e9s importants dels que promouen les entitats privades d&#8217;Espanya i Europa, tant pel nombre de beques convocades com per la varietat de les disciplines. En total, l&#8217;entitat destinar\u00e0 20,2 milions d&#8217;euros a aquesta promoci\u00f3. El programa compta amb el cofinan\u00e7ament de la Comissi\u00f3 Europea a trav\u00e9s de l&#8217;Acci\u00f3 Marie Sk\u0142odowska-Curie COFUND en el context del programa marc Horizon 2020.<\/p>\n<p>Albert Antol\u00edn \u00e9s doctor en Farmacoinform\u00e0tica per la Universitat Pompeu Fabra. Despr\u00e9s de defensar el seu doctorat, va rebre una prestigiosa beca Marie Curie per incorporar-se a l&#8217;Institute of Cancer Research (ICR, Londres, Regne Unit). Posteriorment, la beca postdoctoral Sir Henry Wellcome li va permetre fer una estada al Departament de Biologia de Sistemes de la Columbia University (Nova York, EUA). Despr\u00e9s, el Dr. Antol\u00edn va establir el seu Laboratori de Biologia Qu\u00edmica de Sistemes a l&#8217;ICR el juliol del 2021 gr\u00e0cies a una beca del ICR. I, el setembre del 2022, aquest laboratori es va traslladar a l&#8217;IDIBELL i a l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO) gr\u00e0cies al suport d\u2019aquesta beca Junior Leader de la Fundaci\u00f3 &#8220;la Caixa&#8221;.<\/p>\n<p>L&#8217;objectiu de la seva recerca \u00e9s desenvolupar recursos p\u00fablics de biologia qu\u00edmica per a millorar la reproductibilitat en biomedicina, descobrir com funcionen els f\u00e0rmacs a escala de sistemes per a expandir el seu \u00fas en medicina personalitzada, desenvolupar noves estrat\u00e8gies basades en el Big Data i la intel\u00b7lig\u00e8ncia artificial per al disseny de f\u00e0rmacs multidiana, i descobrir nous tractaments contra el c\u00e0ncer m\u00e9s segurs i efica\u00e7os. Despr\u00e9s d&#8217;haver treballat en el sector industrial farmac\u00e8utic i el m\u00f3n acad\u00e8mic, est\u00e0 particularment interessat en la investigaci\u00f3 translacional per crear ponts entre el descobriment aplicat de f\u00e0rmacs i la comprensi\u00f3 de q\u00fcestions fonamentals encara per resoldre en biologia qu\u00edmica i de sistemes aplicada a la resoluci\u00f3 de malalties com el c\u00e0ncer.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ahir es va celebrar la cerim\u00f2nia d&#8217;entrega de les beques de la Fundaci\u00f3 \u201cla Caixa\u201d. El Dr. Albert Antol\u00edn, investigador principal de l&#8217;IDIBELL i l&#8217;ICO, va rebre una ajuda Junior Leader per a desenvolupar noves estrat\u00e8gies basades en el Big Data i la intel\u00b7lig\u00e8ncia artificial per al disseny de f\u00e0rmacs contra el c\u00e0ncer que previnguin la resist\u00e8ncia als medicaments.<\/p>\n","protected":false},"author":8,"featured_media":23399,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452,519],"tags":[],"class_list":["post-23398","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-de-mama","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure","category-quimica-medica-i-disseny-de-farmacs"],"publishpress_future_action":{"enabled":false,"date":"2024-11-29 01:36:47","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=23398"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23398\/revisions"}],"predecessor-version":[{"id":23400,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/23398\/revisions\/23400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/23399"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=23398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=23398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=23398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}